Two Cases of Possible Exacerbation of Chronic Rejection After Anti-SARS-CoV-2 Messenger RNA Vaccination: A Case Report

Tatsuya Okamoto; Hideaki Okajima; Eri Ogawa; Elena Yukie Uebayashi; Miki Yamamoto; Masashi Kadohisa; Yosuke Yamada; Sachiko Minamiguchi; Hironori Haga; Etsurou Hatano

doi:10.1016/j.transproceed.2022.11.009

Two Cases of Possible Exacerbation of Chronic Rejection After Anti-SARS-CoV-2 Messenger RNA Vaccination: A Case Report

Transplant Proc. 2023 Apr;55(3):530-532. doi: 10.1016/j.transproceed.2022.11.009. Epub 2022 Nov 30.

Authors

Affiliations

¹ Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto Japan. Electronic address: okamotot@kuhp.kyoto-u.ac.jp.
² Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto Japan; Department of Pediatric Surgery, Kanazawa Medical University, Kanazawa, Japan.
³ Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto Japan.
⁴ Department of Diagnostic Pathology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Abstract

In post-liver transplant recipients, SARS-CoV-2 infection is a health threat, and novel messenger RNA vaccines such as Pfizer BioNTech BNT162b2 and Moderna mRNA-1273 are aggressively recommended. However, there are few reports on their adverse effects, some of which may be potentially fatal. We have experienced 2 post-liver transplant recipients with exacerbated chronic rejection after vaccination, one of whom had to undergo retransplant and the other who is still in the process of liver function without improvement. These alarming cases will be presented as case reports.

Publication types

Case Reports

MeSH terms

COVID-19 Vaccines* / adverse effects
COVID-19* / prevention & control
Graft Rejection* / etiology
Humans
Liver Transplantation
SARS-CoV-2
Transplant Recipients*
Vaccination / adverse effects

Substances

COVID-19 Vaccines